Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Francis X. Parnis"'
Autor:
Irfan Cicin, Elizabeth R. Plimack, Howard Gurney, Raya Leibowitz, Boris Y. Alekseev, Francis X. Parnis, Avivit Peer, Andrea Necchi, Joaquim Bellmunt, Hiroyuki Nishiyama, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Thomas Powles, Cora N. Sternberg
Publikováno v:
BMC Cancer, Vol 23, Iss S1, Pp 1-11 (2024)
Abstract Background Indoleamine 2,3-dioxygenase 1 (IDO1) levels correlate with poor outcomes in urothelial carcinoma (UC). IDO1 and programmed death-ligand 1 (PD-L1) are often co-expressed. Epacadostat is a potent and highly selective inhibitor of ID
Externí odkaz:
https://doaj.org/article/263d9199baf8485699909ce6591e41d9
Autor:
Andrea Necchi, Michiel S. Van der Heijden, Dmytro Trukhin, Avivit Peer, Howard Gurney, Boris Y. Alekseev, Francis X. Parnis, Raya Leibowitz, Maria De Santis, Petros Grivas, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Arjun V. Balar, Ronald de Wit
Publikováno v:
BMC Cancer, Vol 23, Iss S1, Pp 1-11 (2024)
Abstract Background Indoleamine 2,3- dioxygenase 1 (IDO1) is an immunosuppressive enzyme that has been correlated with shorter disease-specific survival in patients with urothelial carcinoma (UC). IDO1 may counteract the antitumor effects of immune c
Externí odkaz:
https://doaj.org/article/37a2f0fcea5140a684940d22b18e5a1a
Publikováno v:
Cancer Imaging, Vol 17, Iss 1, Pp 1-5 (2017)
Abstract Background Haematuria and pelvic pain are recognized and documented adverse reactions related to Cabazitaxel use. To date there has not been any documentation of imaging findings in patients with this presentation. Cases We report a case ser
Externí odkaz:
https://doaj.org/article/b15b7df6175e4785af28c89c9a5e40a5
Autor:
Petros Grivas, Evgeny Kopyltsov, Po-Jung Su, Francis X. Parnis, Se Hoon Park, Yoshiaki Yamamoto, Peter C. Fong, Christophe Tournigand, Miguel A. Climent Duran, Aristotelis Bamias, Claudia Caserta, Jane Chang, Paul Cislo, Alessandra di Pietro, Jing Wang, Thomas Powles
Publikováno v:
European urology.
In JAVELIN Bladder 100, avelumab first-line maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS; primary endpoint) versus BSC alone in patients with advanced urothelial carcinoma (aUC) without disease progression
Publikováno v:
Cancer Imaging, Vol 17, Iss 1, Pp 1-5 (2017)
Cancer Imaging
Cancer Imaging
Background Haematuria and pelvic pain are recognized and documented adverse reactions related to Cabazitaxel use. To date there has not been any documentation of imaging findings in patients with this presentation. Cases We report a case series of fi
Autor:
Martin Borg, Wan Mohd Nazri Wan Zainon, Francis X. Parnis, E Hillenband, B Higgs, D Kotasek, S Hamzah, Eric Yeoh
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 5:17-23
Aim: To evaluate two cases of gemcitabine-induced radiation recall in patients who were treated for localized pancreatic cancer, and review the literature. Methods: The two cases of radiation recall (from a cohort of 80 patients treated for pancreati
Autor:
A Lim, Martin Borg, Eric Yeoh, Julie Butters, G. Gill, G Rush, Gelareh Farshid, M. Bochner, Ian N. Olver, T van Doorn, James Kollias, D Kotasek, Francis X. Parnis
Publikováno v:
Australasian Radiology. 51:53-61
Summary The aims of this study were to evaluate the feasibility, practicality, efficacy and safety of the delivery of accelerated partial breast irradiation using the MammoSite for the boost phase. Six patients aged 53–69 years with stage T1N0, T2N
Publikováno v:
Anti-cancer drugs. 20(10)
Chordomas are rare tumors arising from the axial skeleton. The disease is characterized by slow local growth, frequent local recurrences, and rare systemic spread. Surgery and local radiation remains the mainstay of treatment with minimal role of sys
Publikováno v:
American journal of clinical oncology. 20(3)
Twenty-two patients with advanced transitional cell bladder cancer were treated in a phase II trial exploring the possible synergy of cisplatin and interferon alpha 2b. Of the 20 evaluable patients, 7 (35%) had a partial response to the treatment, an
Autor:
Peter C. O'Brien, Francis X. Parnis
Publikováno v:
Acta oncologica (Stockholm, Sweden). 34(1)
Radiotherapy is rarely used as salvage therapy following chemotherapy failure in Hodgkin's disease. Analysis of our experience identified only 11 cases from over 400 patients treated, and data from other centres are similarly sparse. Three (43%) of 7